Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple Blood Test Could Make It Easier to Diagnose Epilepsy

By LabMedica International staff writers
Posted on 14 Mar 2023

Epilepsy refers to abnormal activity in the brain that results in temporary loss of control of behavior and movement. More...

This condition can be congenital, caused by a tumor, stroke, or brain infection, and produce varying symptoms based on the affected region of the brain. Diagnosing epilepsy can be a challenging and resource-intensive process, and differentiating it from other conditions is often difficult. As such, there exists a pressing need to develop better diagnostic tools, particularly for use early on after a suspected seizure. Now, researchers have discovered higher levels of immune proteins in the blood before and after an epileptic seizure that could serve as possible biomarkers, allowing for accurate diagnosis of epilepsy using a simple blood test.

Researchers from Lund University (Lund, Sweden) began looking for potential biomarkers for epilepsy within the immune system as the inflammation processes that begin as an immune response in the body are also capable of provoking a seizure. The researchers also conducted a comparative analysis of epileptic seizures with psychogenic non-epileptic seizures which is a psychiatric diagnosis that can exhibit clinical symptoms closely resembling those witnessed in epilepsy, thus leading to frequent misdiagnosis. Psychogenic seizure is a chronic disorder that remains underdiagnosed and is usually erroneously treated with epilepsy medication. As such, there is a compelling need for a more straightforward differentiation method between the two conditions.

By analyzing the blood samples of individuals who recently experienced epileptic seizures, researchers identified a significant increase in the levels of five distinct inflammation markers or proteins. Conversely, for individuals experiencing psychogenic seizures, there was no notable variation in the biomarker concentration. This suggests that a simple blood test administered to patients arriving at the emergency room following a seizure could reveal elevated immunological responses, indicating the possibility of an epileptic seizure. In contrast, if these biomarker levels are normal, there is a greater likelihood of a psychogenic seizure, thereby offering an initial indication of how the patient should be evaluated further.

“We call these markers ‘fingerprints’ since they involve several inflammation-related proteins with different reaction patterns,” said Marie Taylor, physician, and doctoral student in the research team. “The patients who had epilepsy showed raised levels of one of the five proteins – IL-6 – even before their seizures, a value that transiently raised even further directly after the seizure.”

“The next stage is to repeat our studies on a broader and less homogenous patient group, where we investigate the ‘fingerprint’ in adults with epilepsy,” added Christine Ekdahl Clementson, group leader, and associate professor at Lund University. “We also want to see whether the biomarkers respond in the same way in children, where the causes of epilepsy are more often genetic.”

Related Links:
Lund University 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.